BioAtla (BCAB) Competitors $0.33 +0.00 (+0.45%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$0.35 +0.02 (+4.68%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. ELUT, CRVO, PYXS, BYSI, SRZN, FBRX, VNRX, IGMS, IMMX, and CNTXShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Elutia (ELUT), CervoMed (CRVO), Pyxis Oncology (PYXS), BeyondSpring (BYSI), Surrozen (SRZN), Forte Biosciences (FBRX), VolitionRx (VNRX), IGM Biosciences (IGMS), Immix Biopharma (IMMX), and Context Therapeutics (CNTX). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Its Competitors Elutia CervoMed Pyxis Oncology BeyondSpring Surrozen Forte Biosciences VolitionRx IGM Biosciences Immix Biopharma Context Therapeutics BioAtla (NASDAQ:BCAB) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership. Do institutionals and insiders have more ownership in BCAB or ELUT? 77.2% of BioAtla shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 11.5% of BioAtla shares are held by insiders. Comparatively, 27.6% of Elutia shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, BCAB or ELUT? BioAtla has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Elutia has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Is BCAB or ELUT more profitable? BioAtla has a net margin of 0.00% compared to Elutia's net margin of -168.23%. Elutia's return on equity of 0.00% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -373.47% -116.55% Elutia -168.23%N/A -96.70% Do analysts recommend BCAB or ELUT? BioAtla currently has a consensus price target of $5.00, indicating a potential upside of 1,408.30%. Elutia has a consensus price target of $8.00, indicating a potential upside of 302.01%. Given BioAtla's higher probable upside, equities analysts clearly believe BioAtla is more favorable than Elutia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to BCAB or ELUT? In the previous week, Elutia had 2 more articles in the media than BioAtla. MarketBeat recorded 3 mentions for Elutia and 1 mentions for BioAtla. BioAtla's average media sentiment score of 0.46 beat Elutia's score of 0.44 indicating that BioAtla is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elutia 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, BCAB or ELUT? Elutia has higher revenue and earnings than BioAtla. Elutia is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M1.76-$69.78M-$1.22-0.27Elutia$24.38M3.36-$53.95M-$1.93-1.03 SummaryElutia beats BioAtla on 9 of the 16 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.28M$3.02B$5.52B$9.35BDividend YieldN/A2.46%4.73%4.15%P/E Ratio-0.2718.0629.1424.41Price / Sales1.76183.19372.8978.84Price / CashN/A40.5624.4827.20Price / Book1.338.628.515.77Net Income-$69.78M-$54.98M$3.24B$264.99M7 Day Performance-4.63%-0.87%0.65%-0.68%1 Month Performance-12.76%16.08%7.97%7.08%1 Year Performance-78.61%14.18%30.78%23.80% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla1.858 of 5 stars$0.33+0.5%$5.00+1,408.3%-79.2%$19.28M$11M-0.2760News CoverageUpcoming EarningsGap UpELUTElutia3.4675 of 5 stars$1.97+2.6%$8.00+306.1%-33.4%$78.94M$24.38M-1.02180Positive NewsUpcoming EarningsGap UpCRVOCervoMed2.7039 of 5 stars$8.67-3.5%$20.50+136.4%-12.2%$78.15M$9.74M-3.984Upcoming EarningsGap UpHigh Trading VolumePYXSPyxis Oncology2.4523 of 5 stars$1.23-2.0%$9.00+634.7%-68.1%$77.43M$16.15M-0.7760News CoveragePositive NewsGap UpBYSIBeyondSpringN/A$1.92flatN/A+16.8%$77.41M$1.75M0.0080SRZNSurrozen1.8443 of 5 stars$9.31+4.0%$38.50+313.5%+39.6%$76.64M$10.65M-0.3780News CoverageUpcoming EarningsGap DownFBRXForte Biosciences3.1294 of 5 stars$11.63+0.3%$61.00+424.5%+46,070.5%$76.37MN/A-0.715Positive NewsVNRXVolitionRx1.4913 of 5 stars$0.73-2.6%$3.50+379.3%-2.1%$75.94M$1.31M-2.0380News CoverageGap UpIGMSIGM Biosciences4.2357 of 5 stars$1.26-0.8%$5.50+336.5%-85.1%$75.91M$2.68M-0.39190Earnings ReportHigh Trading VolumeIMMXImmix Biopharma2.6694 of 5 stars$2.72+0.4%$7.00+157.4%+18.7%$75.55MN/A-3.899News CoveragePositive NewsUpcoming EarningsCNTXContext Therapeutics2.6165 of 5 stars$0.85+1.1%$5.50+547.1%-70.3%$75.44MN/A-2.747Positive NewsUpcoming Earnings Related Companies and Tools Related Companies ELUT Alternatives CRVO Alternatives PYXS Alternatives BYSI Alternatives SRZN Alternatives FBRX Alternatives VNRX Alternatives IGMS Alternatives IMMX Alternatives CNTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
